论文部分内容阅读
目的探讨肝癌血清高迁移率族蛋白B1(HMGB-1)的表达及与p53的相关性和临床病理特征的关系。方法酶联免疫吸附剂测定法(ELISA)检测20例肝细胞癌、20例肝内胆管细胞癌患者和20例健康志愿者血清HMGB-1和p53表达。结果血清HMGB-1在肝细胞癌组[(83.8±17.4)ng/ml]和胆管细胞癌组[(95.9±21.4)ng/ml]的表达均高于健康对照组[(8.4±2.6)ng/ml],差异均有统计学意义(P<0.05);血清p53在肝细胞癌组[(251.0±45.6)pg/ml]和胆管细胞癌组[(267.8±47.4)pg/ml]的表达均高于健康对照组[(160.0±28.4)pg/ml],差异均有统计学意义(P<0.05)。HMGB-1和p53的表达在肝细胞癌组和肝内胆管细胞癌组血清中均呈正相关(r=0.660 3,P<0.05;r=0.614 2,P<0.05);血清HMGB-1和p53水平与患者年龄、性别、肿瘤大小和肿瘤数目无相关性(P>0.05),与肿瘤TNM分期、分化程度、淋巴转移情况相关(P<0.05)。结论肝癌血清HMGB-1的表达与p53具有相关性,二者共同影响肝癌临床病理。
Objective To investigate the relationship between the expression of high mobility group box-1 (HMGB-1) and the correlation with p53 and clinicopathological features in hepatocellular carcinoma. Methods Serum levels of HMGB-1 and p53 were detected by enzyme linked immunosorbent assay (ELISA) in 20 patients with hepatocellular carcinoma, 20 patients with intrahepatic cholangiocarcinoma and 20 healthy volunteers. Results The serum levels of HMGB-1 in hepatocellular carcinoma (83.8 ± 17.4 ng / ml) and cholangiocarcinoma (95.9 ± 21.4 ng / ml) were significantly higher than those in healthy controls [(8.4 ± 2.6) ng / ml], the difference was statistically significant (P <0.05); The expression of serum p53 in hepatocellular carcinoma group [(251.0 ± 45.6) pg / ml] and cholangiocarcinoma group [(267.8 ± 47.4) pg / ml] All higher than those in healthy control group [(160.0 ± 28.4) pg / ml], the difference was statistically significant (P <0.05). The expression of HMGB-1 and p53 was positively correlated with the serum level of HCC and intrahepatic cholangiocarcinoma (r = 0.6603, P <0.05; r = 0.614 2, P <0.05) There was no correlation between the level and the patient’s age, sex, tumor size and the number of tumor (P> 0.05), and was correlated with TNM stage, differentiation degree and lymphatic metastasis (P <0.05). Conclusion The expression of HMGB-1 in hepatocellular carcinoma has a correlation with p53, both of which influence the clinicopathology of HCC.